Wellcovorin

(Leucovorin)

ApprovedSmall molecule

Leucovorin is used to reduce the toxic side effects of certain cancer medications, particularly methotrexate, and to enhance the effectiveness of some cancer treatments. It's also used to treat a type of anemia caused by folate deficiency.[2] Wellcovorin is currently approved and in use across 73 indications[4].[1]

Wellcovorin is one of 1206 small molecule programs targeting Pancreatic Neoplasm. It is currently in Approved.

Indications

386

Total Trials

Active Trials

1,205

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Pancreatic NeoplasmApproved

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Colorectal CarcinomaActive, not recruiting

MetastasisActive, not recruiting

Esophageal Squamous Cell CarcinomaActive, not recruiting

Esophageal CarcinomaActive, not recruiting

Gallbladder CarcinomaActive, not recruiting

Nasopharyngeal CarcinomaActive, not recruiting

Depressive DisorderApproved

Biliary Tract DiseaseApproved

Pancreatic NeoplasmApproved

Approved

Gastroesophageal Junction AdenocarcinomaPhase 3

Active, not recruiting

Colorectal CarcinomaPhase 2

Active, not recruiting

MetastasisPhase 1/Phase 2

Active, not recruiting

Esophageal Squamous Cell CarcinomaPhase 2

Active, not recruiting

Esophageal CarcinomaPhase 3

Active, not recruiting

Gallbladder CarcinomaPhase 2

Active, not recruiting

Nasopharyngeal CarcinomaPhase 3

Active, not recruiting

Depressive DisorderApproved

Approved

Biliary Tract DiseaseApproved

Approved

Showing 10 of 73 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Wellcovorin

GGlaxo Dba Glaxosmithkline

Approved

6 2

Trodelvy

Gilead

Preclinical

37 3

Tykerb

GSK

Preclinical

80 4

Halaven

Eisai

Preclinical

38 5

Tecentriq

Roche

Preclinical

36 6

Adriamycin

GGynecologic Oncology Group

Preclinical

87 7

Avastin

BBio-Thera Solutions

Preclinical

153 8

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 9

Prolia

Amgen

Preclinical

14 10

Gemzar

GGynecologic Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Acute Lymphoblastic Leukemia

NCT01920737

Phase 2Recruiting

Intestinal Cancer

NCT03800693

Q4 2026

Phase 2Active, not recruiting

Patients With Locally Advanced Rectal Cancer

NCT02008656

Phase 1Recruiting

Locally Advanced or Metastatic Solid Tumors

NCT03715933

Phase 1Active, not recruiting

Metastatic Colorectal Cancer

NCT06011772

Phase 2Recruiting

Unresectable

NCT05727163

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer26 trials

A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer

Active, not recruiting·AAkeso·Phase 2·NCT05382442·254 enrolled

A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer

Completed· Roche logo

Roche·Phase 3·NCT00069108·627 enrolled

FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

Recruiting·GGruppo Oncologico del Nord-Ovest·Phase 3·NCT06733038·238 enrolled

Show 23 more trials

Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer

Withdrawn·MMerrimack Pharmaceuticals·Phase 1/2·NCT02785068

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Active, not recruiting·RRoswell Park Cancer Institute·Phase 1·NCT06011772·2 enrolled

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Active, not recruiting· Pfizer logo

Pfizer·Phase 3·NCT04607421·831 enrolled

Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)

Terminated· Gilead logo

Gilead·Phase 2·NCT05330429·77 enrolled

A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT01490866·70 enrolled

Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193219·36 enrolled

Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT02138617·100 enrolled

A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer

Unknown status· Jiangsu Simcere Pharmaceutical Co., Ltd. logo

Jiangsu Simcere Pharmaceutical Co., Ltd.·Phase 1·NCT02453464·36 enrolled

FOLFIRI Versus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer Patients

Unknown status·FFudan University·Phase 3·NCT02935764·164 enrolled

Clinical Trial in Patients With Metastatic Colorectal Cancer

Completed·MMast Therapeutics, Inc.·Phase 2·NCT00235898·300 enrolled

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT05253651·400 enrolled

Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients

Completed·TThe Affiliated Hospital of the Chinese Academy of Military Medical Sciences·Phase 2/3·NCT01523431·583 enrolled

5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.

Recruiting·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 1/2·NCT04689347·27 enrolled

Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT03050814·30 enrolled

A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00040391

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT04008030·839 enrolled

A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer

Completed· Roche logo

Roche·Phase 4·NCT01588990·128 enrolled

Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)

Completed· Roche logo

Roche·Phase 2·NCT01374425·376 enrolled

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.

Withdrawn· Roche logo

Roche·Phase 2·NCT00577109

Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)

Terminated·OOHSU Knight Cancer Institute·Phase 2·NCT00642746·16 enrolled

Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer

Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT00126256·570 enrolled

A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer

Unknown status·11Globe Health Institute·Phase 3·NCT03522649·668 enrolled

Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver

Withdrawn·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03069950

Colorectal Cancer22 trials

A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer

Completed·IIsofol Medical AB·Phase 3·NCT03750786·490 enrolled

Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients

Completed·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT02414009·82 enrolled

Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer

Completed·JJohn Hays·Phase 2·NCT01652196·56 enrolled

Show 19 more trials

Efficacy and Safety Study of Recombinant Endostatin Combined With Chemotherapy to Treat Advanced Colorectal Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT01529164·51 enrolled

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

Recruiting· Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd·Phase 2·NCT06948448·144 enrolled

A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00001576·28 enrolled

Colorectal Cancer Metastatic

Completed· Sanofi logo

Sanofi·Phase 3·NCT01670721·175 enrolled

Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer

Withdrawn·WWeill Medical College of Cornell University·Phase 2·NCT02046538

Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients

Completed·GGruppo Oncologico Italiano di Ricerca Clinica·Phase 2·NCT04072198·73 enrolled

Colorectal Cancer (CRC) Cetuximab Elderly Frail

Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT01522612·5 enrolled

Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer

Terminated·AAIO-Studien-gGmbH·Phase 2·NCT00889343·101 enrolled

Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement

Terminated·WWashington University School of Medicine·Phase 2·NCT00537823·9 enrolled

Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients

Unknown status·FFudan University·Phase 2·NCT02376452·100 enrolled

A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer

Terminated·NNuCana plc·Phase 2·NCT05678257·180 enrolled

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03169777

An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2/3·NCT03414983·196 enrolled

DC-CIK Immunotherapy Plus Chemotherapy vs Chemotherapy Alone in the Adjuvant Treatment of Stage III Colorectal Cancer

Unknown status·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 2/3·NCT02415699·100 enrolled

Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer

Terminated·UUniversity of Miami·Phase 2·NCT00449163·25 enrolled

FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer

Completed·—·Phase 1/2·NCT01206530·50 enrolled

Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT01164215·76 enrolled

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

Completed·NNSABP Foundation Inc·Phase 2·NCT00803647·20 enrolled

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT05239741·100 enrolled

Pancreatic Cancer18 trials

QUILT-3.080: NANT Pancreatic Cancer Vaccine

Terminated·IImmunityBio, Inc.·Phase 1/2·NCT03586869·3 enrolled

Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer

Active, not recruiting·SSeoul National University Hospital·Phase 2·NCT04447092·77 enrolled

A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer

Terminated·—·Phase 2·NCT05546411·8 enrolled

Show 15 more trials

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

Recruiting·MMayo Clinic·Phase 2·NCT06381154·25 enrolled

Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer

Completed·SStanford University·Phase 3·NCT01926197·27 enrolled

Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy

Completed·WWashington University School of Medicine·Phase 1·NCT03883919·20 enrolled

Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer

Completed· Sanofi logo

Sanofi·Phase 3·NCT01121848·108 enrolled

Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 1·NCT01821612·23 enrolled

PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment

Not yet recruiting·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT07028424·206 enrolled

A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03336216·205 enrolled

FOLFIRINOX + NIS793 in Pancreatic Cancer

Terminated·—·Phase 1·NCT05417386·4 enrolled

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1·NCT02231723·139 enrolled

Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer

Unknown status·—·Phase 1·NCT03703063·30 enrolled

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

Recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT03977233·45 enrolled

QUILT-3.088: NANT Pancreatic Cancer Vaccine

Withdrawn·IImmunityBio, Inc.·Phase 2·NCT03563144

QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Terminated·IImmunityBio, Inc.·Phase 1/2·NCT03387098·4 enrolled

Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer

Completed·MMerrimack Pharmaceuticals·Phase 3·NCT01494506·417 enrolled

A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment

Completed· Ipsen logo

Ipsen·Phase 3·NCT04083235·770 enrolled

Gastric Cancer12 trials

Perioperative Chemotherapy in Gastric Cancer

Terminated·UUkrainian Society of Clinical Oncology·Phase 2·NCT04937738·69 enrolled

Postoperative Chemoradiation or Chemotherapy After Preoperative Chemotherapy for Gastric Cancers

Terminated·TTannaz Armaghany·Phase 1·NCT03515941·6 enrolled

FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01913639·39 enrolled

Show 9 more trials

5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer

Completed·KKrankenhaus Nordwest·Phase 2/3·NCT01216644·716 enrolled

Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer.

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT01715233·27 enrolled

Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers

Withdrawn·WWashington University School of Medicine·Phase 2·NCT02296671

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

Completed· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 3·NCT02625610·499 enrolled

Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer

Active, not recruiting·—·Phase 2·NCT03764553·320 enrolled

Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt-

Recruiting·SSt. Petersburg State Pavlov Medical University·N/A·NCT04595929·304 enrolled

Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers

Withdrawn·OOhio State University Comprehensive Cancer Center·Phase 1·NCT05296005

Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04354662·35 enrolled

Home Parenteral Nutrition for Malnourished Unresectable Stage IV Gastric Cancer

Completed·KKaohsiung Medical University Chung-Ho Memorial Hospital·N/A·NCT03121807·25 enrolled

Acute Lymphoblastic Leukemia6 trials

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT05032183·4 enrolled

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02828358·78 enrolled

PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Active, not recruiting·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1/2·NCT03817320·24 enrolled

Show 3 more trials

Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT02420717·11 enrolled

A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01920737·39 enrolled

A Study in Adults With Untreated Acute Lymphoblastic Leukemia

Completed·—·Phase 2·NCT00136435·100 enrolled

67 more indications

Breast Cancer5 trials

Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer

Unknown status·AAdherex Technologies, Inc.·Phase 2·NCT01231802·140 enrolled

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03175666

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

Terminated·IImmunityBio, Inc.·Phase 1/2·NCT03387085·9 enrolled

Show 2 more trials

QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine

Withdrawn·IImmunityBio, Inc.·Phase 2·NCT03554109

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Active, not recruiting·EEnliven Therapeutics·Phase 1·NCT06328738·275 enrolled

Advanced Solid Tumors4 trials

A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03184870·332 enrolled

A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors

Recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 1/2·NCT06139211·186 enrolled

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

Recruiting· GSK logo

GSK·Phase 1·NCT07277270·84 enrolled

Show 1 more trial

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors

Completed· Gilead logo

Gilead·Phase 1·NCT01803282·236 enrolled

Esophageal Cancer4 trials

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Completed· Roche logo

Roche·Phase 1/2·NCT03281369·214 enrolled

Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery

Completed·UUniversity of Miami·Phase 2·NCT00448760·29 enrolled

A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01246960·168 enrolled

Show 1 more trial

Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer

Completed·WWashington University School of Medicine·Phase 2·NCT01928290·67 enrolled

Esophageal Adenocarcinoma4 trials

AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas

Not yet recruiting·AAmerican Association for Cancer Research·Phase 2·NCT07290985·121 enrolled

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT06469944·160 enrolled

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 2·NCT03929666·74 enrolled

Show 1 more trial

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Recruiting· AbbVie logo

AbbVie·Phase 2·NCT06628310·180 enrolled

Pancreatic Ductal Adenocarcinoma4 trials

Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting·UUniversity of Miami·Phase 2·NCT07096362·50 enrolled

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Completed· Roche logo

Roche·Phase 1/2·NCT03193190·341 enrolled

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Active, not recruiting· Revolution Medicines logo

Revolution Medicines·Phase 3·NCT06625320·501 enrolled

Show 1 more trial

Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma

Completed·CCardiff Oncology·Phase 2·NCT04752696·41 enrolled

Chemotherapy4 trials

Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy

Terminated·MM.D. Anderson Cancer Center·N/A·NCT00673179·7 enrolled

Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM

Terminated·SSun Yat-sen University·Phase 3·NCT03500874·92 enrolled

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

Recruiting· Astellas logo

Astellas·Phase 1·NCT07024615·25 enrolled

Show 1 more trial

A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

Completed· Incyte logo

Incyte·Phase 1/2·NCT03314935·149 enrolled

Pancreatic Adenocarcinoma4 trials

Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Recruiting·JJonsson Comprehensive Cancer Center·Phase 1/2·NCT05688215·56 enrolled

A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma

Completed·EEndeavor Health·Phase 2·NCT01660711·22 enrolled

Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Completed·OOncolytics Biotech·Phase 1·NCT02620423·11 enrolled

Show 1 more trial

Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

Unknown status·CCSPC Ouyi Pharmaceutical Co., Ltd.·Phase 2·NCT05047991·153 enrolled

Methotrexate4 trials

Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01737671·7 enrolled

A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT05445440·30 enrolled

A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03402087·30 enrolled

Show 1 more trial

A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT05615012·76 enrolled

Adenocarcinoma4 trials

Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT00082706·46 enrolled

FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum

Terminated·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00077233·238 enrolled

NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)

Completed·CCancer Trials Ireland·Phase 3·NCT01726452·377 enrolled

Show 1 more trial

FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III)

Unknown status·—·Phase 2·NCT04442984·326 enrolled

Locally-advanced Rectal Cancer3 trials

Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02921256·363 enrolled

Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer

Completed·GGrupo Espanol Multidisciplinario del Cancer Digestivo·Phase 2·NCT02340949·180 enrolled

SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer

Recruiting·UUniversity of Miami·Phase 1·NCT05412082·25 enrolled

Patients With Locally Advanced Rectal Cancer3 trials

A Study of Avastin (Bevacizumab) Plus Xeloda (Capecitabine) in Patients With Locally Advanced Rectal Cancer.

Completed· Roche logo

Roche·Phase 2·NCT01227707·43 enrolled

Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT02008656·358 enrolled

Preoperative Radiotherapy and Chemotherapy in Patients With Locally Advanced Rectal Cancer

Completed·TTrans Tasman Radiation Oncology Group·Phase 2·NCT01013805·41 enrolled

Fluorouracil3 trials

Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination

Completed· Sanofi logo

Sanofi·Phase 1·NCT00507091·24 enrolled

Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC

Terminated·FFox Chase Cancer Center·Phase 2·NCT03099486·2 enrolled

Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01046864·49 enrolled

Mantle Cell Lymphoma3 trials

S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00041132·56 enrolled

R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma

Completed·UUniversity of Miami·Phase 2·NCT00450801·22 enrolled

Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma

Completed·UUniversity of Miami·Phase 2·NCT00878254·25 enrolled

Colon Cancer3 trials

A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer

Completed· Roche logo

Roche·Phase 3·NCT00009737·1,987 enrolled

PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer

Unknown status·VVastra Gotaland Region·N/A·NCT02959541·48 enrolled

Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

Active, not recruiting·NNRG Oncology·Phase 2/3·NCT04068103·635 enrolled

Liver Metastases2 trials

ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05062317·120 enrolled

Folfox-B Study for Patients With Colorectal Liver Metastases

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00508872·2 enrolled

Lymphoma2 trials

Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma

Terminated·UUniversity of Miami·Phase 2·NCT01964755·6 enrolled

Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00267865·12 enrolled

Pembrolizumab2 trials

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Recruiting· Astellas logo

Astellas·Phase 1/2·NCT05083481·366 enrolled

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06576037·128 enrolled

Treatment2 trials

FOLFIRINOX for 2nd-line Treatment of BTC

Completed·—·Phase 2·NCT03778593·34 enrolled

SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial

Completed· Amgen logo

Amgen·Phase 2·NCT00418938·266 enrolled

Myelodysplastic Syndrome2 trials

Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05146739·8 enrolled

Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Terminated·SSt. Jude Children's Research Hospital·Phase 1·NCT02676323·19 enrolled

Bevacizumab2 trials

Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc

Terminated·—·Phase 2·NCT00755118·24 enrolled

Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00941499·140 enrolled

Patients With Solid Tumors2 trials

Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors

Terminated·WWellstat Therapeutics·Phase 1·NCT00044785·24 enrolled

A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors

Unknown status·SSuZhou Stainwei Biotech Inc.·Phase 1·NCT03503604·18 enrolled

Solid Tumors2 trials

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Recruiting· Eli Lilly logo

Eli Lilly·Phase 1·NCT06586515·630 enrolled

First in Human Study of AZD9592 in Solid Tumors

Recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT05647122·403 enrolled

Intestinal Cancer2 trials

Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

Completed·AAnne Noonan·Phase 1·NCT04164069·9 enrolled

2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers

Recruiting·EEmory University·Phase 2·NCT03800693·60 enrolled

Locally Advanced or Metastatic Solid Tumors2 trials

A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT01633970·240 enrolled

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Recruiting·IInhibrx Biosciences, Inc·Phase 1·NCT03715933·321 enrolled

Radiation Therapy2 trials

Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer

Recruiting·JJonsson Comprehensive Cancer Center·Phase 1·NCT04703101·25 enrolled

Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT03300544·3 enrolled

Locally Advanced1 trial

HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC

Approved for marketing·MMing Zhao··NCT02436044

High Grade Neuroendocrine Cancer1 trial

Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin

Terminated·RRoswell Park Cancer Institute·Phase 2·NCT03736720·11 enrolled

Efficacy1 trial

A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)

Recruiting·BBelgian Group of Digestive Oncology·Phase 2·NCT05472259·134 enrolled

Neoadjuvant Chemotherapy1 trial

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

Recruiting·CCanadian Cancer Trials Group·Phase 3·NCT06205485·250 enrolled

Colon Carcinoma1 trial

Randomized Trial on Adjuvant Chemotherapy in Colon Carcinoma Dukes B

Completed·AAustrian Breast & Colorectal Cancer Study Group·Phase 3·NCT00309543·636 enrolled

Advanced Solid Malignancies1 trial

A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies

Completed· Sanofi logo

Sanofi·Phase 1·NCT01930552·20 enrolled

Urothelial Cancer1 trial

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03197571

Advanced or Metastatic Solid Tumors1 trial

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Recruiting· Pfizer logo

Pfizer·Phase 1·NCT07318805·260 enrolled

Rectal Cancer1 trial

A Single Arm Trial of Oxaliplatin and 5FU With Concurrent Radiation in Patients With Metastatic Rectal Cancer

Completed·PPeter MacCallum Cancer Centre, Australia·Phase 2·NCT00422864·26 enrolled

Advanced Cancer1 trial

A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02124148·167 enrolled

Unresectable1 trial

FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients

Recruiting·SSun Yat-sen University·Phase 2·NCT05727163·194 enrolled

Biliary Cancer1 trial

NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer

Active, not recruiting·GGeorgetown University·Phase 2·NCT04005339·48 enrolled

Sandhoff disease1 trial

Pyrimethamine as a Treatment for Late-Onset GM2-gangliosidosis (Tay-Sachs and Sandhoff Disease)

Completed·TThe Hospital for Sick Children·Phase 1/2·NCT01102686·20 enrolled

Chemoradiation1 trial

Neo-adjuvant Chemoradiation With Oxaliplatin/5-FU in Rectal Cancer

Completed·—·Phase 2·NCT00831181·27 enrolled

Hepatocellular Carcinoma1 trial

Sorafenib + mFOLFOX for Hepatocellular Carcinoma

Completed·MMassachusetts General Hospital·Phase 2·NCT01775501·40 enrolled

Biliary Tract Cancer1 trial

Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer

Terminated·CCSPC Ouyi Pharmaceutical Co., Ltd.·Phase 2·NCT05009953·17 enrolled

Unresectable Colorectal Liver Metastases1 trial

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Recruiting·EECOG-ACRIN Cancer Research Group·Phase 3·NCT05863195·408 enrolled

Glioblastoma Multiforme1 trial

A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies

Unknown status·LLeaf Vertical Inc.·Phase 1/2·NCT03607643·160 enrolled

Stage III Colon Cancer1 trial

Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer

Unknown status·HHellenic Oncology Research Group·Phase 3·NCT01308086·2,000 enrolled

PD-1antibody1 trial

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Active, not recruiting· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Phase 2·NCT05945823·53 enrolled

Merkel Cell Carcinoma1 trial

QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03167164

Randomized1 trial

Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC

Completed·HHellenic Oncology Research Group·Phase 3·NCT00469443·330 enrolled

CRC1 trial

Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM

Active, not recruiting·SSun Yat-sen University·Phase 2·NCT03493048·146 enrolled

Neurotoxicity1 trial

Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

Completed· Sanofi logo

Sanofi·Phase 3·NCT00305188·879 enrolled

Osteosarcoma1 trial

A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response

Terminated·UUniversity of Chicago·Phase 1·NCT01258634·2 enrolled

Adjuvant Chemotherapy1 trial

Immunoscore As Decision Guidance for Adjuvant Chemotherapy in Colon Cancer

Withdrawn·—·Phase 3·NCT04488159

Nasopharyngeal Carcinoma1 trial

Comparison the Effects of Different Neoadjuvant Chemotherapy Regimen on Acute Toxicity, Tumor Response, and Survival in Patients With Advanced Nasopharyngeal Carcinoma

Unknown status·TTaichung Veterans General Hospital·Phase 3·NCT02500940·54 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma

Recruiting·RRoswell Park Cancer Institute·Phase 2·NCT05651594·40 enrolled

Induction Therapy1 trial

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

Terminated·UUniversity of California, San Francisco·Phase 2·NCT00632827·21 enrolled

Prognosis1 trial

Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT02099175·41 enrolled

Colorectal Carcinoma1 trial

Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00176774·24 enrolled

Melanoma1 trial

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03167177

Squamous Cell Carcinoma1 trial

Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and Neck

Completed·—·Phase 1/2·NCT00139243·30 enrolled

Esophageal Carcinoma1 trial

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT04949256·864 enrolled

Rectal Adenocarcinoma1 trial

Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma

Withdrawn·UUniversity of Texas Southwestern Medical Center·Phase 1/2·NCT01302613

Head and Neck Squamous Cell Carcinoma1 trial

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03169764

Hematologic Malignancies1 trial

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Recruiting·—·Phase 1·NCT05292664·30 enrolled

Ovarian Cancer1 trial

QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03197584

Gastroesophageal Junction1 trial

Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors

Completed·VVanderbilt University·Phase 2·NCT00515216·26 enrolled

Leukemia1 trial

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00133991·23 enrolled

Central Nervous System Lymphoma1 trial

LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03684980·58 enrolled

Trial1 trial

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Terminated·OOHSU Knight Cancer Institute·Phase 1·NCT03878524·2 enrolled

Regulatory

FDA Approval Timeline[5]

Jul 8, 1983

WELLCOVORIN

NDA NDA018342

Jan 30, 1986

LEUCOVORIN CALCIUM

NDA NDA018459

Jan 30, 1987

LEUCOVORIN CALCIUM

NDA NDA008107

Feb 3, 2026

VYKOURA

NDA NDA220406

Sources

References

[1]
ClinicalTrials.gov — 386 trial records for Leucovorin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Wellcovorin drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Leucovorin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Leucovorin. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA220406). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Wellcovorin. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Glaxo Dba Glaxosmithkline company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: GGlaxo Dba Glaxosmithkline

Patent Landscape[6]

Patent Cliff

Dec 23, 2044

Earliest patent expiration — generic entry possible after this date

Patent #Expires

12564592Dec 23, 2044